• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 4, 2019

View Archived Issues

Editas and Bluerock find mutual benefit in deal to develop new allogeneic cell therapies

Editas Medicine Inc. and Bluerock Therapeutics LP have agreed to combine their respective genome editing and cell therapy technologies to discover, develop and manufacture a set of new off-the-shelf cell therapies targeting a broad array of indications. Editas will focus on oncology, including solid tumors and blood cancers, while Bluerock will work on neurology, cardiology and immunology indications. Potential products based on the approach are likely several years away. But Cindy Collins, interim CEO of Editas, said she is optimistic about their value. Read More

Atlas Venture puts the muscle in Dyne's $50M series A round

Dyne Therapeutics Inc., founded and seeded last year by Atlas Venture, has completed a $50 million series A along with Forbion and MPM Capital. Cambridge, Mass.-based Dyne will target therapies for patients suffering from myotonic dystrophy type 1 (DM1), a rare and inherited disorder with life-limiting complications that affects about 40,000 people in the U.S. alone. Read More

Congress advancing efforts to make the price of medicine go down

Nearly 50 bills dealing with some aspect of taming drug prices have been introduced so far this year in the U.S. Senate or House, but the six bills slated for markup Wednesday in the House Energy and Commerce Committee are likely to be the first of the lot to come up for a floor vote in either chamber. Read More

Finding their way in BTK: Aptose, others research resistance-beating ploys

With the recent granting of the IND for trials to begin with CG-806 in the hands of Aptose Biosciences Inc., the rich and busy field of Bruton's tyrosine kinase (BTK) inhibitors may be set to further evolve. Read More

Gottlieb: FDA should prod 503A pharmacies to attain 503B status

The swan song of FDA Commissioner Scott Gottlieb in the U.S. House Appropriations Committee came with the not-unexpected rueful farewells from both sides of the political aisle, but Gottlieb said one of his hopes for the agency is that it would push some compounding pharmacies operating under Section 503A of the Food, Drug and Cosmetic Act to register as 503B pharmacies. That would create more regulatory liability for those pharmacies, but Gottlieb said the FDA stands ready to assist any pharmacies with the tools and knowledge to make that transition. Read More

Adrenomed readies for success as lead drug adrecizumab clears interim hurdle in sepsis trial

DUBLIN – By the end of the year, Adrenomed AG will have a pretty good idea whether its lead drug candidate, adrecizumab, is a runner in what is one of the most challenging of all indications. A phase II trial of the drug in patients with early septic shock has already passed an interim efficacy analysis in half of the 300 patients the study is enrolling. The company aims to complete the study this year – and it could then be in a position to contemplate applying for conditional marketing authorization in Europe. Read More

Other news to note

Cellgen Diagnostics Inc., of Irvine, Calif., and Genomic Testing Cooperative are collaborating to accelerate global development of companion tests for various oncology therapeutics, using GTC's next-generation sequencing, artificial intelligence-based biomarker discovery services and Cellgen's companion diagnostics platform. Financial terms were not disclosed. Read More

Appointments and advancements

Geron Corp., of Menlo Park, Calif., appointed Dawn C. Bir and Elizabeth G. O'Farrell to its board. Bir will serve on its nominating and corporate governance committee and O'Farrell will serve on its audit committee. Read More

Financings

Santhera Pharmaceuticals AG, of Pratteln, Switzerland, said it entered a CHF15 million (US$15.04 million) credit line facility. It is also preparing for the issuance of up to 500,000 registered shares in a private placement managed by Mirabaud Securities (Geneva). In addition, Santhera is considering various options to monetize certain assets, which would provide for additional nondilutive funding. Read More

Clinical data for April 3, 2019

Read More

Regulatory actions for April 3, 2019

Read More

Conference Data: American Association of Cancer Research

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe